Ascendis Pharma A/S (NASDAQ:ASND) Trading 5.9% Higher – Still a Buy?

Shares of Ascendis Pharma A/S (NASDAQ:ASND) shot up 5.9% during mid-day trading on Monday . The company traded as high as $136.88 and last traded at $136.82. 266,899 shares traded hands during trading, a decline of 35% from the average session volume of 409,644 shares. The stock had previously closed at $129.19.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Evercore ISI lifted their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a report on Tuesday, September 17th. JPMorgan Chase & Co. lowered their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research report on Wednesday, October 23rd. Bank of America boosted their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Stifel Nicolaus raised their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Finally, Citigroup upped their price target on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and a consensus target price of $192.07.

Ascendis Pharma A/S Price Performance

The stock’s 50-day moving average price is $132.84 and its 200 day moving average price is $133.54. The firm has a market capitalization of $8.19 billion, a PE ratio of -16.69 and a beta of 0.65.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Rhumbline Advisers grew its position in shares of Ascendis Pharma A/S by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after buying an additional 143 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its stake in Ascendis Pharma A/S by 42.0% in the second quarter. Oppenheimer Asset Management Inc. now owns 6,927 shares of the biotechnology company’s stock worth $945,000 after acquiring an additional 2,048 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Ascendis Pharma A/S by 5.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company’s stock worth $233,348,000 after acquiring an additional 93,185 shares in the last quarter. Seven Eight Capital LP increased its position in Ascendis Pharma A/S by 245.4% during the 2nd quarter. Seven Eight Capital LP now owns 15,876 shares of the biotechnology company’s stock valued at $2,165,000 after purchasing an additional 11,279 shares during the period. Finally, Simplify Asset Management Inc. bought a new stake in shares of Ascendis Pharma A/S in the 2nd quarter valued at about $1,211,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.